Back

Yuhan targets 2026 Phase 1 results for oral HER2 cancer drug

Verifying
  • Yuhan disclosed the Phase 1/2 trial design and status for oral cancer drug YH42946.
  • 2026 Phase 1 results are targeted by year-end, with two dose levels planned for Phase 2.
  • Yuhan licensed YH42946 technology from J INTS BIO in 2023.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.